JP2017526339A5 - - Google Patents

Info

Publication number

JP2017526339A5

JP2017526339A5 JP2016573964A JP2016573964A JP2017526339A5 JP 2017526339 A5 JP2017526339 A5 JP 2017526339A5 JP 2016573964 A JP2016573964 A JP 2016573964A JP 2016573964 A JP2016573964 A JP 2016573964A JP 2017526339 A5 JP2017526339 A5 JP 2017526339A5

Authority

JP

Japan

Prior art keywords

antibody

domain

axl

seq

nucleic acid

Prior art date

2015-06-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108020004707 nucleic acids Proteins 0.000 claims 19
• 150000007523 nucleic acids Chemical class 0.000 claims 19
• 102000039446 nucleic acids Human genes 0.000 claims 19
• 238000000034 method Methods 0.000 claims 16
• 125000003275 alpha amino acid group Chemical group 0.000 claims 13
• 239000000203 mixture Substances 0.000 claims 9
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
• 210000004027 cell Anatomy 0.000 claims 5
• 201000010099 disease Diseases 0.000 claims 5
• 239000003814 drug Substances 0.000 claims 5
• 239000000427 antigen Substances 0.000 claims 4
• 102000036639 antigens Human genes 0.000 claims 4
• 108091007433 antigens Proteins 0.000 claims 4
• 238000004519 manufacturing process Methods 0.000 claims 4
• 150000001413 amino acids Chemical class 0.000 claims 3
• 208000035475 disorder Diseases 0.000 claims 3
• 239000012634 fragment Substances 0.000 claims 3
• 208000037819 metastatic cancer Diseases 0.000 claims 3
• 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 3
• 230000002018 overexpression Effects 0.000 claims 3
• 229940124597 therapeutic agent Drugs 0.000 claims 3
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
• 229940123309 Immune checkpoint modulator Drugs 0.000 claims 2
• 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
• 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 108700026244 Open Reading Frames Proteins 0.000 claims 2
• 238000007792 addition Methods 0.000 claims 2
• 201000011510 cancer Diseases 0.000 claims 2
• 239000003153 chemical reaction reagent Substances 0.000 claims 2
• 238000012217 deletion Methods 0.000 claims 2
• 230000037430 deletion Effects 0.000 claims 2
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
• 238000000338 in vitro Methods 0.000 claims 2
• 238000003780 insertion Methods 0.000 claims 2
• 230000037431 insertion Effects 0.000 claims 2
• 238000005259 measurement Methods 0.000 claims 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims 2
• 230000002062 proliferating effect Effects 0.000 claims 2
• 238000006467 substitution reaction Methods 0.000 claims 2
• 239000003053 toxin Substances 0.000 claims 2
• 231100000765 toxin Toxicity 0.000 claims 2
• MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
• -1 DVD-lg Proteins 0.000 claims 1
• 238000009007 Diagnostic Kit Methods 0.000 claims 1
• 108090000790 Enzymes Proteins 0.000 claims 1
• 102000004190 Enzymes Human genes 0.000 claims 1
• 101000973901 Homo sapiens Tyrosine-protein kinase Mer Proteins 0.000 claims 1
• 241000288906 Primates Species 0.000 claims 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
• 101150098329 Tyro3 gene Proteins 0.000 claims 1
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 1
• 239000004480 active ingredient Substances 0.000 claims 1
• 108010023337 axl receptor tyrosine kinase Proteins 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 238000001514 detection method Methods 0.000 claims 1
• 239000000032 diagnostic agent Substances 0.000 claims 1
• 229940039227 diagnostic agent Drugs 0.000 claims 1
• 238000000375 direct analysis in real time Methods 0.000 claims 1
• 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 1
• 102000045684 human MERTK Human genes 0.000 claims 1
• 238000012986 modification Methods 0.000 claims 1
• 230000004048 modification Effects 0.000 claims 1
• 239000002773 nucleotide Substances 0.000 claims 1
• 125000003729 nucleotide group Chemical group 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 238000012360 testing method Methods 0.000 claims 1